"Virus-like particles: A practical alternative to cultured rubella virus"

Non-infectious VLPs perfectly mimic the surface of infectious virus particles. This not only makes them a safe, efficient and scalable solution for vaccine development, but also means they hold great promise in the field of diagnostics, as they can bind and capture immunoglobulin M (IgM) antibodies that arise during primary infection. The aim of this whitepaper is to discuss the mechanisms, applications and benefits of VLPs in research and development, and the potential that these inactive virus particles hold for improving the diagnosis and prevention of rubella.

The whitepaper will cover:

•     the background and evolution of virology;

•     the production and mechanisms of VLPs;

•     The Native Antigen Company’s VLP portfolio;

•     potential applications of VLPs in research and development; and

•     the specific application of VLPs for the diagnosis and management of rubella.

• Life Sciences

• Healthcare System

• Data science

• Pharma and Life Sciences

• Telemedicine

• Lifecycle Management